CD63 Antibody from SICGEN ANTIBODIES
Search, find, compare suppliers for anti-CD63 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD63 |
| Clone | polyclonal |
| Host Species | Goat |
| Reactive Species | human, mouse, rat, bovine, canine, chicken/avian, donkey, feline, goat, guinea pig, hamster, horse, porcine, rabbit, sheep, simian |
| Isotype | n/a |
| Format | epitope affinity purified |
| Size | 600 µg |
| Concentration | 3 mg/ml |
| Applications | n/a |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | RRID: AB_2333130. CD63 is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of the members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. These proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. This protein is a cell surface glycoprotein that is known to complex with integrins. It may function as a blood platelet activation marker. Reacts with CD63, a 40-60 kDa glycoprotein, detected by Western blot in the following human (HeLa, HUH, Jurkat), mouse (AtT-20, Hepa, 3T3, RAW264.7), canine (MDCK) and monkey (COS-7) whole cell lysates. |
| Immunogen | Purified recombinant peptide derived from within residues 120 aa to 175 aa of human CD63 produced in E. coli. |
| Other Names | CD63 antigen, CD63 antigen (melanoma 1 antigen), granulophysin, LAMP-3, lysosomal-associated membrane protein 3, lysosome-associated membrane glycoprotein 3, ME491, melanoma-associated antigen, melanoma 1 antigen, melanoma-associated antigen ME491, MLA1, ocular melanoma-associated antigen, OMA81H, tetraspanin-30, TSPAN30 antibody. |
| Gene, Accession # | Accession: ENSG00000135404 |
| Catalog # | AB0047-200 |
| Price | 320 € |
| Order / More Info | CD63 Antibody from SICGEN ANTIBODIES |
| Product Specific References | 1. Amorim M, Martins B, Caramelo F, et al. Front Med (Lausanne) 2022 May. PMID: 35692536 2. Matsui T, Sakamaki Y, Nakashima S, et al. Cell Rep 2022 May. PMID: 35649370 3. Martins-Marques T, Costa MC, Catarino S, et al. EMBO Rep 2022 May. PMID: 35593040 4. Ferreira JV, Soares AR, Ramalho J, et al. Sci Adv 2022 Mar. PMID: 35333565 5. Saludas L, Garbayo E, Ruiz-Villalba A, et al. Eur J Pharm Biopharm 2021 Dec. PMID: 34968647 6. Garbayo E, Ruiz-Villalba A, Hernandez SC, et al. Acta Biomater 2021 May. PMID: 33716175 7. Aires ID, Ribeiro-Rodrigues T, Boia R, et al. Glia 2020 Dec. PMID: 32645245 8. Martins-Marques T, Ribeiro-Rodrigues T, de Jager SC, et al. Life Sci Alliance 2020 Oct. PMID: 33097557 9. Armando F, Gambini M, Corradi A, et al. Viruses 2020 Feb. PMID: 32054075 10. Simpong LD, PhD Thesis Universitat Leipzig, Germany 2020 11. Carvalho AS, Moraes MCS, Hyun Na C, et al. Cancers 2020 Nov. PMID: 33233545 12. Ferreira JV, Rosa Soares A, Ramalho JS, et al. PLoS One 2019 Oct. PMID:31613922 13. Cardoso MHS, PhD Thesis, NOVA University of Lisbon, Portugal 2018 14. Martins-Marques T, Pinho MJ, Zuzarte M. et al. J Extracell Vesicles 2016 Sep 29;5:32538. PMID:27702427 15. Successfully validated (Western Blotting) by Center for Diabetes and Metabolic Diseases, Indiana University, US |
SICGEN ANTIBODIES
SICGEN ANTIBODIES
Research and Development in Biotechnology Ltd
BIOCANT PARK Nucleo 04, Lt 03
3060-196 Cantanhede PORTUGAL
P: +351 91 9145219
F: +351 21 458 21 89
information@sicgen.pt
Technical Support: technical@sicgen.pt
http://www.sicgen.pt
Profile of SICGEN ANTIBODIES
Return to Antibodies